Patent History
  • Application
    EP 20110839154 2011-11-11
  • Publication
    EP 2638061 2013-09-18
Supplementary

Patent: SOLUBLE PD-1 VARIANTS, FUSION CONSTRUCTS, AND USES THEREOF

TitleSOLUBLE PD-1 VARIANTS, FUSION CONSTRUCTS, AND USES THEREOF
Priority Date2010-11-11 US 12/412557P
2011-11-11 PCT/CN2011082087
Inventors
Issue Date2013
Citation
EP Published Patent application EP 2638061. European Patent Office (EPO), Escapenet, 2013 How to Cite?
AbstractThe subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In additon, the subject invention can be used in the prevention and/or treatment of tumor or cancer.
Persistent Identifierhttp://hdl.handle.net/10722/213666
References

 

DC FieldValueLanguage
dc.date.accessioned2015-08-11T03:28:52Z-
dc.date.available2015-08-11T03:28:52Z-
dc.date.issued2013-
dc.identifier.citationEP Published Patent application EP 2638061. European Patent Office (EPO), Escapenet, 2013-
dc.identifier.urihttp://hdl.handle.net/10722/213666-
dc.description.abstractThe subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In additon, the subject invention can be used in the prevention and/or treatment of tumor or cancer.-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License for public patent documents-
dc.titleSOLUBLE PD-1 VARIANTS, FUSION CONSTRUCTS, AND USES THEREOF-
dc.typePatent-
dc.identifier.authorityCHEN, ZHIWEI=rp00243-
dc.description.naturepublished_or_final_version-
dc.contributor.inventorCHEN, ZHIWEI-
dc.contributor.inventorZHOU, JINGYING-
patents.identifier.applicationEP 20110839154-
patents.description.assigneeUNIV HONG KONG [CN]-
patents.description.countryEuropean Patent Office-
patents.date.publication2013-09-18-
dc.relation.referencesWO 2010027828 (A2) 2010-03-11-
dc.relation.referencesW O2010027828 (A3) 2010-08-26-
dc.relation.referencesXP 002718124-
dc.relation.referencesWO 2010027828 (A2) 2010-03-11-
dc.relation.referencesW O2010027828 (A3) 2010-08-26-
dc.relation.referencesXP 003031878-
dc.relation.referencesXP 003031879-
dc.relation.referencesWO 2010027828 (A2) 2010-03-11-
dc.relation.referencesW O2010027828 (A3) 2010-08-26-
patents.identifier.hkutechidAIDS-2010-00369-2-
patents.identifier.hkutechidAIDS-2010-00369-3-
patents.identifier.hkutechidAIDS-2010-00369-4-
patents.identifier.hkutechidAIDS-2010-00369-5-
patents.identifier.hkutechidAIDS-2010-00369-6-
patents.date.application2011-11-11-
patents.date.priority2010-11-11 US 12/412557P-
patents.date.priority2011-11-11 PCT/CN2011082087-
patents.description.ccep-
patents.identifier.publicationEP 2638061-
patents.relation.familyCN 103261217 (A) 2013-08-21-
patents.relation.familyUS 2012121634 (A1) 2012-05-17-
patents.relation.familyU S9029315 (B2) 2015-05-12-
patents.relation.familyWO 2012062218 (A1) 2012-05-18-
patents.description.kindA1-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats